June 12, 2007; 68 (24 suppl 4) Articles
Neutralizing antibodies to interferon
Avertano Noronha
First published June 11, 2007, DOI: https://doi.org/10.1212/01.wnl.0000277705.63813.84
Neutralizing antibodies to interferon
Avertano Noronha
Neurology Jun 2007, 68 (24 suppl 4) S16-S22; DOI: 10.1212/01.wnl.0000277705.63813.84
Citation Manager Formats
Make Comment
See Comments

Article Information
vol. 68 no. 24 suppl 4 S16-S22
PubMed:
Print ISSN:
Online ISSN:
History:
- First Published June 11, 2007.
Copyright & Usage:
© 2007
Author Disclosures
- Avertano Noronha, MB, MD
- Avertano Noronha, MB, MD
- Address correspondence and reprint requests to Dr. Avertano Noronha, Department of Neurology, University of Chicago, 5841 South Maryland Ave., Chicago, IL 60637 anoronha{at}neurology.bsd.uchicago.edu
Article usage
Cited By...
Letters: Rapid online correspondence
No comments have been published for this article.
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
- Article
- Abstract
- NABS: BIOLOGICAL RESPONSE MARKERS AND ASSAYS
- NAB PREVALENCE IN MS CLINICAL TRIALS
- CLINICAL AND IMAGING PARAMETERS IN NAB+ PATIENTS
- PERSISTENCE OF NABS: HIGH-AFFINITY NABS IN IFN-β1A-TREATED PATIENTS
- SUBOPTIMAL TREATMENT RESPONSE TO INTERFERON
- IMMUNOREGULATORY EFFECTS OF NABS: IMMUNE COMPLEXES
- NOTE ADDED IN PROOF
- Footnotes
- REFERENCES
- Figures & Data
- Info & Disclosures
Advertisement
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Articles
Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosisTimothy K. Vartanian, Scott S. Zamvil, Edward Fox et al.Neurology, December 13, 2004 -
Articles
Monoclonal antibodies in MSMechanisms of actionBibiana Bielekova, Brenda L. Becker et al.Neurology, December 28, 2009 -
Articles
Identifying and treating patients with suboptimal responsesB. A. Cohen, O. Khan, D. R. Jeffery et al.Neurology, December 28, 2004 -
Introduction
Anti-IFNβ antibodies in IFNβ-treated MS patientsSummaryAndrew R. Pachner et al.Neurology, November 10, 2003